Navigation Links
New research may overturn conventional wisdom on drug-resistant tuberculosis

A newly released study suggests that the majority of cases of drug-resistant tuberculosis (TB) among patients undergoing treatment for the disease may be due to new infections, not acquired resistance. If confirmed in future studies the research, in the March 15 issue of The Journal of Infectious Diseases, may drive a major shift in strategy for controlling TB.

A major difficulty in treating patients with pulmonary TB is that the organism can become progressively resistant to standard therapy. This resistance was long thought to be acquired through mutations in the infecting strain when the treatment regimen was inadequate or the patient did not comply with it. More recently, studies of the genetic make-up of Mycobacterium tuberculosis (M. tuberculosis) strains have shown that resistance can also result from re-infection with a new strain that is already drug-resistant, sometimes against multiple drugs.

The authors of the new study, Qian Gao, PhD, and coworkers in Shanghai, China and elsewhere, used molecular genetics and drug susceptibility testing to investigate patients with TB who were treated in Shanghai hospitals during 1999-2004. They focused on 38 patients from whom samples were available before and during treatment. The researchers found that the strains of TB in the samples taken before treatment were genetically different from those taken during treatment in 87 percent (33 out of 38) of patients.

To determine the relative proportion of drug resistance caused by re-infection or mutation, the authors excluded six patients who were initially infected with resistant TB and then became drug-susceptible or resistant to fewer drugs. In the remaining 32 patients, the initial sample was drug-susceptible or resistant to at least one drug and the subsequent sample resistant to one or more drugs. Of these patients, 84 percent (27 patients) had before-and-during samples with different genetic patterns and only 16 percent (5 patients) had id
'"/>

Source:Infectious Diseases Society of America


Page: 1 2 3

Related biology news :

1. Columbia research lifts major hurdle to gene therapy for cancer
2. U of M researcher examines newly emerging deadly disease
3. NYU researchers simulate molecular biological clock
4. First atlas of key brain genes could speed research on cancer, neurological diseases
5. New research questions basic tenet of neuron function
6. Vital step in cellular migration described by UCSD medical researchers
7. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
8. UCSD researchers maintain stem cells without contaminated animal feeder layers
9. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
10. New protein discovered by Hebrew University researchers
11. First real-time view of developing neurons reveals surprises, say Stanford researchers
Post Your Comments:
(Date:8/1/2014)... cell research will provide enormous opportunities for both ... could replicate any other cells in the body, ... damaged spinal cords, treating kidney, liver and lung ... for profit is staggering. Prof. Jinhui Chen from ... of research still faces myriad biological, ethical, legal, ...
(Date:8/1/2014)... component of phloem, the conductive tissue through which plants ... Elongated cylindrical cells are capped at one end by ... tubes which in turn form a network throughout a ... special cells which play an important role in carbon ... about their differentiation," says Professor Yk Helariutta from the ...
(Date:8/1/2014)... August 1, 2014 The Journal of Nutrition Education ... Best Great Educational Material (GEM) awards, which were presented ... annual conference, "Nutrition Education Impact: Local to Global," in ... These annual awards recognize the authors of the best ... as judged by members of the JNEB Journal Committee ...
Breaking Biology News(10 mins):Developmental regulation of important plant phloem components discovered 2
... confirmed that research done with zebrafish may be able to ... of cancer and the mutations that can lead to it ... is essential to preventing tumors. , The findings were published ... Sciences, by researchers from Oregon State University and two Boston ...
... wellbeing, say researchers in this week's BMJ. The theory ... nature. , Use of wildlife in some therapies is ... Smaller animals (for example, squirrels, owls, and raccoons) have ... and behavioural problems. , People who take part in ...
... modified (GM) maize growing in open field trials. , ... after discovering that a technician had sprayed a restricted ... called stem borers. , Wilson Songa, Kenya's agriculture secretary ... could compromise the validity of the trial's results. , ...
Cached Biology News:Zebrafish may hold key to improved cancer research 2Zebrafish may hold key to improved cancer research 3Kenya halts first field trials of GM maize 2
(Date:8/1/2014)... The  PROPEL Center  of the  iBIO Institute , dedicated ... life sciences companies in Illinois , ... help Illinois entrepreneurs attend ... Chicago .   AdvaMed 2014 is ... , bringing more than 1,000 companies together in ...
(Date:8/1/2014)... August 1, 2014 According to ... "Biophotonics Market - Global Industry Analysis, Size, Share, Growth, ... valued at USD 25.16 billion in 2013, which is ... at a CAGR of 10.4% from 2014 to 2020. ... http://www.transparencymarketresearch.com/biophotonics-market.html Increasing demand for accurate early ...
(Date:8/1/2014)... -- Research and Markets has announced the ... Genotyping and Analysis Market 2014-2018" report to their ... Single Nucleotide Polymorphism (SNP) genotyping is the screening ... genome of various species. SNPs are commonly present in ... can analyze thousands of SNPs and has the potential ...
(Date:8/1/2014)... August 01, 2014 Once a decision ... cost? This webinar will discuss how to define your ... Join speakers Bob Allen, Senior Director of Facilities Integration ... Engineering at Fluor Industrial Services, and special guest Carrier ... Planning at Amgen, as they provide an examination of ...
Breaking Biology Technology:iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 2iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 3iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 4Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 3Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 4Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018 2Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2
... Cord Blood America, Inc . (OTC BB: CBAI, CBAID) announced ... 80 percent of its shareholders voting in a recent proxy vote, ... The one for one hundred reverse split reduces the ... A "D" will be placed on the ticker symbol ...
... BALTIMORE, May 6, 2011 Stenting is safe and ... venous stenosis in patients with deep vein thrombosis (DVT), ... Late-Breaking Clinical Trial at the Society for Cardiovascular Angiography ... EVISTA-DVT focused on patients with blocked veins ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... extracellular matrix for the diabetes, cancer, dermatology ... the first quarter 2011. (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ... duration of action observed in our first ultrafast insulin ...
Cached Biology Technology:Study Shows Stents Are Superior to Balloons Alone for Patients With Deep Venous Thrombosis 2Halozyme Therapeutics Reports First Quarter 2011 Financial Results 2Halozyme Therapeutics Reports First Quarter 2011 Financial Results 3Halozyme Therapeutics Reports First Quarter 2011 Financial Results 4Halozyme Therapeutics Reports First Quarter 2011 Financial Results 5Halozyme Therapeutics Reports First Quarter 2011 Financial Results 6
Request Info...
... materials necessary for the isolation and preparation of ... Kit Components: Erythrocyte ... containing 220 mL of buffered ammonium chloride. (NH ... No. 5113) One bottle containing 220 mL of ...
... with suspension (non-adherent) cells, RNA ... filtration or centrifugation to separate ... Compatible with 96-well GenePlate®. RiboCap™ ... package sizes and contain the ...
... The Zero Background/Kan Cloning Kit ... kanamycin resistance for selection in ... utilizes positive selection to eliminate ... all of the reagents you ...
Biology Products: